TITLE

The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe

AUTHOR(S)
Lançon, Christophe; Toumi, Mondher; Sapin, Christophe; Hansen, Karina
PUB. DATE
January 2008
SOURCE
BMC Psychiatry;2008, Vol. 8, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: After sertindole's suspension, health authorities established a specific named-patient use (NPU) programme in order to supply sertindole to patients who did not respond to or did not tolerate alternative treatments. This programme provided the possibility of prospectively following an exhaustive cohort of patients treated with sertindole after its suspension. A survey was performed to assess sertindole's modalities of prescription, assess and document any serious adverse events (SAEs), and assess the mortality rate within the NPU cohort. Methods: The study comprised a survey of sertindole-treated patients in eleven European countries. All patients treated with sertindole within the NPU programme were eligible for the study. Results: 1,432 patients were included in the study. The reason for sertindole prescription was lack of efficacy (approximately 50%) or adverse events (approximately 20%) of other antipsychotic treatments. The mean sertindole dose was 13.4 mg daily. Lack of efficacy and adverse events were reported as reasons for sertindole discontinuation. A total of 97 SAEs were recorded, including ten fatal outcomes, which occurred during the study period or within thirty days after sertindole discontinuation. The all-cause mortality rate was 0.51 per 100 Person-Years of Exposure (95% Poisson confidence interval: 0.23-0.97). QTc prolongation was reported in 15 patients (1.05% of total patients), being a rate of 0.85 per 100 Person-Years of Exposure [95% CI: 0.48-1.41]. Conclusion: Although prescribing and supplying sertindole were subject to administrative constraints, a significant number of patients were treated with sertindole, thus supporting the need for sertindole in specific cases. Trial registration number: Not applicable.
ACCESSION #
35702814

 

Related Articles

  • PENN-LED INTERNATIONAL STUDY FINDS NO DIFFERENCE IN NONSUICIDE MORTALITY BETWEEN TWO ANTI-PSYCHOTIC DRUGS.  // Psychiatry (1550-5952);Nov2010, Vol. 7 Issue 11, p10 

    The article reports on the findings of a study conducted by the University of Pennsylvania School of Medicine which focuses on the nonsuicide mortality rates of schizophrenics under antipsychotics in Philadelphia, Pennsylvania. It mentions that the study was published online in the November 2010...

  • Clozapine as treatment of first choice in first psychotic episodes. What do we know? Vera, Ignacio; Rezende, Livia; Molina, Vicente; Sanz-Fuentenebro, Javier // Actas Espanolas de Psiquiatria;sep/oct2012, Vol. 40 Issue 5, p281 

    Schizophrenia is currently conceptualized as a neurodevelopmental disorder with progressive clinical, neurophysiological and neurostructural deterioration mostly occurring at early stages of the disease. During the last years, several early intervention programs have tried to modify the natural...

  • Clozapina como tratamiento de primera elección en primeros episodios psicóticos ¿qué sabemos? Vera, Ignacio; Rezende, Livia; Molina, Vicente; Sanz-Fuentenebro, Javier // Actas Espanolas de Psiquiatria;sep/oct2012, Vol. 40 Issue 5, p281 

    Schizophrenia is currently conceptualized as a neurodevelopmental disorder with progressive clinical, neurophysiological and neurostructural deterioration mostly occurring at early stages of the disease. During the last years, several early intervention programs have tried to modify the natural...

  • Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Lambert, Tim // Australian Prescriber;Aug2011, Vol. 34 Issue 4, p97 

    Antipsychotic medications are widely prescribed and carry a variable propensity to cause weight gain and its attendant sequelae - hyperglycaemia, hypertension and hyperlipidaemia. These metabolic risks, along with smoking and poor lifestyle habits, occur between two and five times more often in...

  • Common antipsychotics fuel doubts about safety, efficacy. Newman, Elizabeth // McKnight's Long-Term Care News;Jan2013, Vol. 34 Issue 1, p6 

    The article focuses on the findings of a study that says that off-label use of antipsychotic medication lacks safety and effectiveness in older adults.

  • Dementia drugs hasten mental decline. Motluk, Alison // New Scientist;02/01/97, Vol. 153 Issue 2067, p9 

    Highlights the effects of neuroleptic drug on elderly people reported by Rupert McShane and colleagues at Warnerford Hospital reported in the January 1997 issues of the `British Medical Journal.' Loss of cognitive abilities; Increased aggression; Sleep problems; Paranoia.

  • Antipsychotics. Johnson, Steven T.; Chase, Sandra; Cerrato, Paul L. // RN;Aug97, Vol. 60 Issue 8, p45 

    Focuses on antipsychotic drugs. Examination of the side effects of the drugs; Information to help patients with adverse effects to the drugs; Description of various effects drug can have; Drug interaction; Differences between various families of drugs.

  • Paliperidone overdose.  // Reactions Weekly;5/8/2010, Issue 1300, p39 

    The article describes the case of a 28-year-old man with schizophrenia who developed severe anxiety and restlessness, tachycardia and hypertension after an inadvertent paliperidone overdose.

  • Quetiapine.  // Reactions Weekly;5/8/2010, Issue 1300, p44 

    The article describes the case of a 25-year-old woman who experienced weight gain and drowsiness while undergoing quetiapine therapy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics